Fig. 2

a Study schema with RTCT and concurrent, adjuvant or continuous plerixafor. b Tumour regression and regrowth of OCICx 20 with RTCT (30 Gy over 3 weeks) and concurrent or adjuvant plerixafor: no treatment controls (black), RT alone (blue), RTCT (red), RTCT and concurrent plerixafor (purple), RTCT and adjuvant plerixafor for 3 weeks beginning immediately after RTCT (yellow), RTCT and continuous plerixafor for 6 weeks (concurrently for 3 weeks and adjuvantly for 3 weeks) (light green). There were 5–12 mice per treatment arm. 2c Tumour regression and regrowth of OCICx 20 with RTCT (30 Gy over 3 weeks) and 3 vs. 6 weeks of adjuvant plerixafor: no treatment controls (black), RTCT (red), RTCT and adjuvant plerixafor for 3 weeks beginning immediately after RTCT (yellow), RTCT and adjuvant plerixafor for 6 weeks beginning immediately after RTCT (dark green). There were 4–5 mice per treatment arm. In both experiments, tumour size was monitored after treatment using weekly CT imaging and volume was estimated using orthogonal tumour dimensions, assuming an elliptical shape. Time was measured from the start of treatment. 3 w, 3 weeks; 6 w, 6 weeks; 36 w, 36 weeks